{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T20:26:02Z","timestamp":1794428762310,"version":"4.9.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation","doi-asserted-by":"crossref","award":["No.82170189"],"award-info":[{"award-number":["No.82170189"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007129","name":"Shandong Provincial Natural Science Foundation","doi-asserted-by":"crossref","award":["ZR2021YQ51"],"award-info":[{"award-number":["ZR2021YQ51"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Taishan Scholars Program of Shandong Province"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-025-01677-3","type":"journal-article","created":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T17:10:22Z","timestamp":1740849022000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["CAR-NK cell therapy: latest updates from the 2024 ASH annual meeting"],"prefix":"10.1186","volume":"18","author":[{"given":"Ran","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiange","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangxiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,1]]},"reference":[{"issue":"1","key":"1677_CR1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","volume":"16","author":"P Zhang","year":"2023","unstructured":"Zhang P, Zhang G, Wan X. Challenges and new technologies in adoptive cell therapy. J Hematol Oncol. 2023;16(1):97.","journal-title":"J Hematol Oncol"},{"key":"1677_CR2","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s40164-024-00583-7","volume":"13 1","author":"P Yao","year":"2024","unstructured":"Yao P, Liu YG, Huang G, Hao L, Wang R. The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances. Exp Hematol Oncol. 2024;13 1:118.","journal-title":"Exp Hematol Oncol"},{"key":"1677_CR3","doi-asserted-by":"crossref","unstructured":"Thangaraj JL, Lopez E, Kaufman DS. Improved expansion of peripheral blood and iPSC-Derived natural killer cells for clinical applications. Blood; 144 Supplement 1:3439\u20133439.","DOI":"10.1182\/blood-2024-205859"},{"key":"1677_CR4","doi-asserted-by":"crossref","unstructured":"Boje AS, Langner A, Gehlert CL, Reitinger C, Nimmerjahn F, Murga Penas EM et al. A novel platform technology for the development of NK Cell-based Cellu Lar immunotherapies. Blood; 144 Supplement 1:914\u2013914.","DOI":"10.1182\/blood-2024-210243"},{"key":"1677_CR5","doi-asserted-by":"crossref","unstructured":"Liu F, Tarannum M, Zhao Y, Zhang YJ, Ham JD, Lei K et al. One-Step Construction of Allogeneic CAR-NK Cells Preventing Rejection and Mediating Enhanced Anti-Tumor Responses. Blood; 144 Supplement 1:915\u2013915.","DOI":"10.1182\/blood-2024-198167"},{"key":"1677_CR6","doi-asserted-by":"crossref","unstructured":"Wang X, Luo W, Chen Z, Hu Y, Mei H. Co-Expression of IL-15 and CCL21 Strengthens CAR-NK Cells to Eliminate Tumors in Concert with T Cells and Equips Them with Higher PI3K\/AKT\/m TOR Signal Signature. Blood; 144 Supplement 1:4816\u20134816.","DOI":"10.1182\/blood-2024-205045"},{"key":"1677_CR7","doi-asserted-by":"crossref","unstructured":"Jang J, Stanojevic M, Piccinelli S, Sheffer M, Birch GC, Shapiro RM et al. Mesothelin Targeting IL12-Engineered CAR Memory-like NK Cells Demonstr ate Promising Efficacy in Acute Myeloid Leukemia. Blood; 144 Supplement 1:917\u2013917.","DOI":"10.1182\/blood-2024-204369"},{"key":"1677_CR8","doi-asserted-by":"crossref","unstructured":"Sedloev DN, Chen Q, Unglaub JM, Schmitt A, M\u00fcller-Tidow C, Schmitt M et al. Structurally optimized, IL-2-Armored CLL1 CAR-NK cells are highly Pote nt effectors against AML without Hpsc Toxicity. Blood; 144 Supplement 1:3440\u20133440.","DOI":"10.1182\/blood-2024-210286"},{"key":"1677_CR9","doi-asserted-by":"crossref","unstructured":"Yang J, Jiang L, Zhu Z, Yan Y, Fu J, Wei M. CIB315: an allogeneic, off-the-Shelf Anti-GPRC5D iPSC-Derived CAR-NK P roduct targeting multiple myeloma. Blood; 144 Supplement 1:2055\u20132055.","DOI":"10.1182\/blood-2024-210041"},{"key":"1677_CR10","doi-asserted-by":"crossref","unstructured":"Darrah JM, Varadarajan I, Mehta A, Saultz JN, McKinney M, Ghosh M et al. Efficacy and safety of TAK-007, Cord Blood-Derived CD19 CAR-NK cells, in adult patients with Relapsed\/Refractory (R\/R) B-Cell Non-hodgkin Ly Mphoma (NHL). Blood; 144 Supplement 1:95\u201395.","DOI":"10.1182\/blood-2024-194807"},{"key":"1677_CR11","doi-asserted-by":"crossref","unstructured":"Leedom T, Muz B, Magee K, Vadakekolathu J, Arthur L, Tran M et al. W-NK1 Choreographs Innate and Adaptive Immune Responses to Provide a R obust and Durable Anti-AML Response. Blood; 144 Supplement 1:916\u2013916.","DOI":"10.1182\/blood-2024-201812"},{"key":"1677_CR12","doi-asserted-by":"crossref","unstructured":"Cashen AF, Al Malki MMM, Stevens DA, Muffly L, Edwin N, Abadir E et al. WUN101-01: First in Human Human (FIH) Phase 1 Study of WU-NK-101 (W-NK1) in Patients with Relapsed or Refractory (R\/R) Acute Myeloid Leukemia (AML). Blood. 2024; 144 Supplement 1:4257\u20134257.","DOI":"10.1182\/blood-2024-201520"},{"key":"1677_CR13","doi-asserted-by":"crossref","unstructured":"Askanase A, Khalili L, Chang C, Blaus A, Gip P, Karis E et al. A Phase 1 Study of NKX019, an Allogeneic Chimeric Antigen Receptor Nat ural Killer (CAR-NK) Cell Therapy in Patients with Systemic Lupus Eryt hematosus. Blood; 144 Supplement 1:4846.4841-4846.4841.","DOI":"10.1182\/blood-2024-212347"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01677-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01677-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01677-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T17:10:29Z","timestamp":1740849029000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-025-01677-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1677"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01677-3","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,1]]},"assertion":[{"value":"10 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}